Your browser is no longer supported. Please, upgrade your browser.
Settings
SLS SELLAS Life Sciences Group, Inc. daily Stock Chart
SLS [NASD]
SELLAS Life Sciences Group, Inc.
Index- P/E- EPS (ttm)-13.60 Insider Own6.86% Shs Outstand9.28M Perf Week-52.16%
Market Cap15.40M Forward P/E- EPS next Y-2.49 Insider Trans- Shs Float6.20M Perf Month-67.00%
Income-32.10M PEG- EPS next Q-0.97 Inst Own50.90% Short Float10.02% Perf Quarter-70.46%
Sales- P/S- EPS this Y44.10% Inst Trans- Short Ratio2.50 Perf Half Y-78.04%
Book/sh-0.22 P/B- EPS next Y26.10% ROA-51.20% Target Price12.00 Perf Year-90.29%
Cash/sh0.38 P/C4.40 EPS next 5Y- ROE-262.80% 52W Range1.60 - 18.00 Perf YTD-79.96%
Dividend- P/FCF- EPS past 5Y49.60% ROI- 52W High-90.94% Beta1.62
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low1.87% ATR0.40
Employees11 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)13.00 Volatility16.96% 10.28%
OptionableYes Debt/Eq- EPS Q/Q35.40% Profit Margin- Rel Volume3.01 Prev Close1.66
ShortableNo LT Debt/Eq- EarningsMay 30 Payout- Avg Volume248.89K Price1.63
Recom2.00 SMA20-55.66% SMA50-65.54% SMA200-76.19% Volume61,099 Change-1.81%
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Jul-12-18 08:45AM  SELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering GlobeNewswire -30.60%
07:20AM  Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-26-18 07:46AM  SELLAS Life Sciences Announces Proposed Public Offering of Common Stock GlobeNewswire -18.22%
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 08:45AM  SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018 GlobeNewswire
Jun-01-18 08:45AM  SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients GlobeNewswire +6.76%
May-17-18 08:45AM  SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-18 04:30PM  SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM) GlobeNewswire
May-02-18 08:45AM  SELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement GlobeNewswire
Apr-20-18 08:45AM  SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer GlobeNewswire -5.94%
Apr-16-18 09:00AM  SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results GlobeNewswire
Apr-05-18 02:43PM  MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green Yahoo Finance Video
Apr-02-18 12:18PM  What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy Benzinga +150.72%
08:40AM  SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients GlobeNewswire
Mar-29-18 01:59PM  Loss-Making SELLAS Life Sciences Group Inc (NASDAQ:SLS) Expected To Breakeven Simply Wall St.
Mar-21-18 08:45AM  SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary GlobeNewswire +6.20%
Mar-19-18 08:45AM  SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting GlobeNewswire
Mar-15-18 08:45AM  SELLAS Life Sciences Group Announces Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering Composition of Matter for WT-1 Peptides GlobeNewswire
Mar-13-18 04:15PM  SELLAS Life Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-07-18 09:00AM  SELLAS Life Sciences Announces $10,700,000 Private Placement GlobeNewswire -15.33%
Mar-05-18 04:15PM  SELLAS Life Sciences to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-27-18 08:45AM  Data From SELLAS Life Sciences Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematologys Journal, Blood Advances GlobeNewswire
Feb-06-18 08:30AM  SELLAS Life Sciences to Present at Two Upcoming February Investor Conferences GlobeNewswire
Feb-01-18 04:01PM  Women In Bio Announces Jane Wasman Appointed Chair of Sellas Life Sciences Board of Directors GlobeNewswire
Jan-24-18 08:55AM  SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting GlobeNewswire
Jan-23-18 02:03PM  Whats Installed For SELLAS Life Sciences Group Inc (NASDAQ:SLS)? Simply Wall St.
Jan-06-18 03:10PM  What You Must Know About SELLAS Life Sciences Group Incs (NASDAQ:SLS) Major Investors Simply Wall St.
Dec-29-17 04:46PM  SELLAS Life Sciences Group Successfully Completes Business Combination with Galena Biopharma GlobeNewswire
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has completed Phase II clinical trials for the treatment of acute myeloid leukemia and malignant pleural mesothelioma; is in Phase II clinical trials to treat multiple myeloma; and is in various development phases as a potential treatment for ovarian cancer. It also develops NeuVax that is in Phase II clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which have completed early stage trials in ovarian, endometrial, and breast cancers; and GALE-401, an anagrelide controlled release that has completed Phase II clinical trials in patients with essential thrombocythemia, as well as for the treatment of elevated platelets in patients with myeloproliferative neoplasms. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.